- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01956513
Contribution of MRI in the Evaluation of Apparent Diffusion Coefficient and Prediction of Response to Neoadjuvant Chemotherapy in Breast Cancer (ADC)
October 7, 2013 updated by: Centre Jean Perrin
Etude ADC Apport de l'IRM Dans l'évaluation du Coefficient de Diffusion Apparent et prédiction de la réponse à la chimiothérapie néoadjuvante Dans le Cancer du Sein
The main objective of the study is to assess the sensitivity and the specificity of the variation of apparent diffusion coefficient for prediction, after a course of neoadjuvant chemotherapy or after modification of the treatment sequence, the pathological response at the end of chemotherapy
Study Overview
Status
Withdrawn
Intervention / Treatment
Study Type
Interventional
Phase
- Not Applicable
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Age> 18 years.
- Patient suffering from a breast tumor, regardless of the stage and size
- Patient requiring neoadjuvant chemotherapy
- Patient has the ability to undergo 18F-FDG-PET at baseline, at end of cycle 1 and at the end of neoadjuvant treatment before surgery
- Compulsory affiliation to a social security system.
- Obtaining informed consent in writing, signed and dated.
Exclusion Criteria:
- Patient with cognitive or psychiatric disorders.
- Patient deprived of liberty by a court or administrative.
- Patient with signs against the achievement of MRI, mammography and ultrasound
- Patient metastatic
- Patient with prior chemotherapy, radiotherapy and hormone therapy for her breast cancer
- Pregnant women, current lactation
- Patient suffering from uncontrolled diabetes (> 11 mmol / L)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Variation of apparent diffusion coefficient before / after a cycle of neoadjuvant chemotherapy or before / after modification of the treatment sequence and correlated with histologic response
Time Frame: One year
|
One year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Anne BAILLY, MD, Centre Jean Perrin
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2012
Primary Completion (Anticipated)
October 1, 2013
Study Completion (Anticipated)
October 1, 2013
Study Registration Dates
First Submitted
March 16, 2012
First Submitted That Met QC Criteria
October 7, 2013
First Posted (Estimate)
October 8, 2013
Study Record Updates
Last Update Posted (Estimate)
October 8, 2013
Last Update Submitted That Met QC Criteria
October 7, 2013
Last Verified
October 1, 2013
More Information
Terms related to this study
Other Study ID Numbers
- Etude ADC
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Assess the Variation of Apparent Diffusion Coefficient
-
Centre Hospitalier Universitaire, AmiensRecruitingCrohn Disease | Bowel Cleansing | Apparent Diffusion CoefficientFrance
-
Mansoura UniversityUnknownBladder Cancer | Magnetic Resonance Imaging | Diagnoses Disease | Apparent Diffusion CoefficientEgypt
-
Egalet LtdCompletedAssess Pharmacokinetics of Ketorolac Tromethamine Intranasal and Assess Effects of a Oxymetazoline Hydrochloride on the PK of Ketorolac TromethamineUnited Kingdom
-
Sheba Medical CenterCompletedTo Assess Feasibility of the New ApplicationIsrael
-
Assistance Publique Hopitaux De MarseilleTerminatedTo Assess the Tissular and Plasma Kinetics of ErtapenemFrance
-
Lionel BouvetCompleted
-
Ocon Medical Ltd.CompletedTo Assess the Safety, Effectiveness and User Experience of the Scu 300A IUBBulgaria, Romania
-
Henry Ford Health SystemCompletedTo Assess the Changes in Markers of Bone Turnover Over a Six Month Period After Epidural Steroid Inject | To Assess the Changes in Bone Mineral DensityUnited States
-
LivaNovaCompletedAssess the Benefits From the AAISafeR/SafeR Algorithm of Symphony 2550 or REPLYTM DR in a Wide Range of Pacemaker Patients.Italy, France, Spain, United States, Germany, United Kingdom
-
Kasr El Aini HospitalUnknownAssess the Efficacy of Differentiated and Undifferentiated Stem Cell Therapy in Improving Endometrial Receptivity.Egypt
Clinical Trials on MRI (Magnetic resonance imaging)
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingBrain NeoplasmUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingProstate CarcinomaUnited States
-
M.D. Anderson Cancer CenterActive, not recruitingProstate Adenocarcinoma | Prostate CarcinomaUnited States
-
University of MichiganPhilips Healthcare; General ElectricCompleted
-
American College of RadiologyPennsylvania Department of HealthCompleted
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Recruiting
-
University of CincinnatiActive, not recruitingProstate CancerUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Healthy SubjectUnited States
-
Stanford UniversityTerminatedLaryngeal Neoplasms | Head and Neck Cancers | Larynx CancerUnited States
-
Abramson Cancer Center of the University of PennsylvaniaCompletedBrain TumorUnited States